Travelers with cutaneous leishmaniasis cured without systemic therapy

Clinical Infectious Diseases

Volumn 57, Issue 3, 2013, Pages 370-380

  Morizot, G ^a   Kendjo, E ^a   Mouri, O ^a   Thellier, M ^a   Perignon A ^a   Foulet, F ^c   Cordoliani, F ^d   Bourrat, E ^d,e   Laffitte, E ^f   Alcaraz, I ^g   Bodak, N ^h   Ravel, C ^b   Vray, M ⁱ   Grogl, M ^j   Mazier, D ^a   Caumes, E ^a   Lachaud, L ^b   Buffet, P A ^a,k   El Samad, Y ^l   Salle, V ^l   Gounod, N ^m   Dallot, A ⁿ   Belot, G ^o   Pelletier Cunat, S ^o   Belon, M ^p   Verdon, R ^m   Rogeaux, O ^m   Grossetete G ^m   Lesens, O ^q   Clabaut, A ^r   Maus, E ^r   Jouy, L ^m   Gener, G ^s   Perrin, P ^s   Roch, N ^t   Herve, A ^m   Le Duc, D ^u   Cuchet, E ^v   Maubon, D ^v   Hillion, B ^w   Menot, E ^x   Guillemot, F ^y   Beneton Benhard, N ^z   Celerier, P ^z   Dupuis De Fonclare, A L ^aa   Carre, D ^ab   Bourgeois, A ^ac   Marty, P ^ad   Pomares, C ^ad   Meunier, L ^ae   Abergel, H ^m   Timsit, F ^m   Amoric, J C ^m   Busquet, P ^m   Karam, S ^m   Moisson, Y F ^m   Mouly, F ^m   Ortoli, J C ^m   Consigny, P H ⁱ   Jouan, M ⁱ   Caby, F ^a   Datry, A ^a   Hochedez, P ^a   Rozembaum, F ^a   Dumortier, C ^af   Ancelle, T ^ag   Dupin, N ^ag   Paugam, A ^ag   Ranque, B ^ah   Bougnoux, M E ^h   Canestri, A ^h   Galezowsky, M F ^h   Hadj Rabia, S ^h   Hamel, D ^h   Schneider, P ^h   Wolter Desfosses, M ^h   Janier, M ^ai   Baccard, M ^d   Bezier, M ^d   Broissin, M ^d   Colin De Verdiere, N ^d   Durupt, F ^d   Hope Rapp, E ^d   Juillard, C ^d   Levy, A ^d   Moraillon, I ^d   Petit, A ^d   Regner, S ^d   Barthelme, D ^aj   Tamarin, J M ^m   Begon, E ^ak   Strady, C ^al   Gangneux, J P ^am   Carpentier, O ^an   Mechai, F ^ao   Kieffer, C ^ap   Dellestable, P ^aq   Rebauder, S ^ar   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b French Reference Centre on Leishmaniasis   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^g Hôpital Gustave Dron   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ INSTITUT PASTEUR   (France)

^j WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^k SORBONNE UNIVERSITÉ   (France)

^l AMIENS UNIVERSITY HOSPITAL   (France)

^m CHI ^*

ⁿ CHI   (France)

^o HÔPITAL SAINT JACQUES   (France)

^p CHU   (France)

^q UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^r CH   (France)

^s CH Sud Francilien   (France)

^t DIJON UNIVERSITY HOSPITAL   (France)

^u RAYMOND POINCARÉ HOSPITAL   (France)

^v GRENOBLE UNIVERSITY HOSPITAL   (France)

^w CH   (France)

^x CH   (France)

^y Hôpital Nord   (France)

^z CH   (France)

^aa Hôpital militaire   (France)

^ab Jacques Monod Hospital   (France)

^ac MONTPELLIER UNIVERSITY HOSPITAL   (France)

^ad CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^ae NÎMES UNIVERSITY HOSPITAL   (France)

^af BICHAT HOSPITAL   (France)

^ag Hopital Civil ^*  (France)

^ah HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^ai SAINT JOSEPH HOSPITAL   (France)

^aj CH   (France)

^ak CENTRE HOSPITALIER RENÉ DUBOS   (France)

^al HÔPITAL MAISON BLANCHE   (France)

^am RENNES UNIVERSITY HOSPITAL   (France)

^an CH   (France)

^ao SERVICE D ENDOCRINOLOGIE   (France)

^ap HÔPITAL CIVIL   (France)

^aq Hôpital Beauregard   (France)

^ar HÔPITAL PAUL BROUSSE   (France)

more..

Author keywords

Cutaneous leishmaniasis; Intralesional antimony; Liposomal amphotericin B; Miltefosine; Systemic antimony

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; FLUCONAZOLE; MEGLUMINE ANTIMONATE; MILTEFOSINE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AMYLASE BLOOD LEVEL; ANTIMICROBIAL THERAPY; ARTICLE; BLISTER; CHILD; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DRESS SYNDROME; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPEREOSINOPHILIA; INFLAMMATION; LEISHMANIA; LOCAL THERAPY; LYMPHOCYTOPENIA; MACROCYTIC ANEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYALGIA; PARESTHESIA; PATIENT REFERRAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SCHOOL CHILD; SIDE EFFECT; SKIN LEISHMANIASIS; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND CARE;

CUTANEOUS LEISHMANIASIS; INTRALESIONAL ANTIMONY; LIPOSOMAL AMPHOTERICIN B; MILTEFOSINE; SYSTEMIC ANTIMONY;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPROTOZOAL AGENTS; BANDAGES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; TRAVEL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880349927     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit269     Document Type: Article

References (51)

1. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7:581-96.
2. Van Der Vliet D, Le Guern AS, Freitag S, et al. Pseudomonas aeruginosa otochondritis complicating localized cutaneous leishmaniasis: prevention of mutilation by early antibiotic therapy. Am J Trop Med Hyg 2006; 75:270-2.
3. Masmoudi A, Maalej N, Mseddi M, et al. Glucantime injection: benefit versus toxicity [in French]. Med Mal Infect 2005; 35:42-5.
4. Ribeiro AL, Drummond JB, Volpini AC, Andrade AC, Passos VM. Electrocardiographic changes during low-dose, short-term therapy of cutaneous leishmaniasis with the pentavalent antimonial meglumine. Braz J Med Biol Res 1999; 32:297-301.
5. Rodrigues ML, Costa RS, Souza CS, Foss NT, Roselino AM. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis. Rev Inst Med Trop Sao Paulo 1999; 41:33-7.
6. Ezzine Sebai N, Mrabet N, Khaled A, et al. Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases [in French]. Tunis Med 2010; 88:9-11.
7. Sands M, Kron MA, Brown RB. Pentamidine: a review. Rev Infect Dis 1985; 7:625-34.
8. Castello Viguer MT, Echanove Errazti I, Ridocci Soriano F, Esteban Esteban E, Atienza Fernandez F, Cuesta Estelles G. Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate [in Spanish]. Rev Esp Cardiol 1999; 52:533-5.
9. Rodrigues AM, Hueb M, Nery AF, Fontes CJ. Possible cardioprotective effect of angiotensin-converting enzyme inhibitors during treatment of American tegumentary leishmaniasis with meglumine antimoniate. Acta Trop 2007; 102:113-8.
10. Franke ED, Wignall FS, Cruz ME, et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med 1990; 113:934-40.
11. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44:1289-97.
12. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44:350-6.
13. Oliveira LF, Schubach AO, Martins MM, et al. Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 2011; 118:87-96.
14. Bailey MS, Green AD, Ellis CJ, et al. Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel. J R Army Med Corps 2005; 151:73-80.
15. World Health Organization. Control of the leishmaniases: report of a meeting of the WHO Expert Committee on the control of leishmaniases, Geneva, 22-26 March 2010. WHO technical report series 2011; 949:1-185.
16. Buffet PA, Rosenthal E, Gangneux JP, et al. Therapy of leishmaniasis in France: consensus on proposed guidelines [in French]. Presse Med 2011; 40:173-84.
17. Morizot G, Delgiudice P, Caumes E, et al. Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007; 76:48-52.
18. el Darouti MA, al Rubaie SM. Cutaneous leishmaniasis. Treatment with combined cryotherapy and intralesional stibogluconate injection. Int J Dermatol 1990; 29:56-9.
19. Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43:281-3.
20. Asilian A, Sadeghinia A, Faghihi G, Momeni A, Amini Harandi A. The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis. Ann Trop Med Parasitol 2003; 97:493-8.
21. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 2004; 53: 158-66.
22. Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial. J Am Acad Dermatol 2011; 64:606-8.
23. Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD, Pompeu MM. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis 2011; 53: 693-5.
24. Rubiano LC, Miranda MC, Muvdi Arenas S, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 2012; 205:684-92.
25. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, et al. Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 2011; 84:255-60.
26. Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris, 13-15 June 2006. Kinetoplastid Biol Dis 2007; 6:3.
27. Berman J. Recent developments in leishmaniasis: epidemiology, diagnosis, and treatment. Curr Infect Dis Rep 2005; 7:33-8.
28. Ben Salah A, Buffet PA, Morizot G, et al. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 2009; 3:e432.
29. Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am J Trop Med Hyg 1994; 50:107-11.
30. Buffet P, Caumes E, Gentilini M. Treatment of localized cutaneous leishmaniasis [in French]. Ann Dermatol Venereol 1994; 121:503-11.
31. Buffet PA, Morizot G. Cutaneous leishmaniasis in France: towards the end of injectable therapy? [in French]. Bull Soc Pathol Exot 2003; 96:383-8.
32. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992; 46:296-306.
33. Blum JA, Hatz CF. Treatment of cutaneous leishmaniasis in travelers 2009. J Travel Med 2009; 16:123-31.
34. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-5.
35. Magill AJ. Epidemiology of the leishmaniases. Dermatol Clin 1995; 13:505-23.
36. Dedet JP. Leishmania et leishmanioses du continent ame'ricain. Annales de L'Institut Pasteur: Actualités 1993 4:S3-25.
37. Jeddi F, Caumes E, Thellier M, et al. Drug hypersensitivity syndrome induced by meglumine antimoniate. Am J Trop Med Hyg 2009; 80:939-40.
38. Wise ES, Armstrong MS, Watson J, Lockwood DN. Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with NewWorld cutaneous leishmaniasi. PLoS Negl Trop Dis 2012; 6:e1688.
39. Mlika RB, Hamida MB, Hammami H, et al. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia. Dermatol Ther 2012; 25:615-8.
40. Mueller Y, Mbulamberi DB, Odermatt P, Hoffmann A, Loutan L, Chappuis F. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop Med Int Health 2009; 14: 910-7.
41. Chappuis F, Alirol E, Worku DT, Mueller Y, Ritmeijer K. High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B. Antimicrob Agents Chemother 2011; 55: 455-6.
42. Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials. J Am Acad Dermatol 2007; 57:335 e1-29.
43. Tuon FF, Amato VS, Graf ME, Siqueira AM, Nicodemo AC, Amato Neto V. Treatment of New World cutaneous leishmaniasis - a systematic review with a meta-analysis. Int J Dermatol 2008; 47:109-24.
44. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev 2009:CD004834.
45. Gonzalez U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 2008: CD005067.
46. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001; 65:466-70.
47. Lopez L, Robayo M, Vargas M, Velez ID. Thermotherapy: an alternative for the treatment of American cutaneous leishmaniasis. Trials 2012; 13:58.
48. Soto J, Rojas E, Guzman M, et al. Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis. Clin Infect Dis 2013; 56:1255-60.
49. Blum J, Lockwood DNJ, Visser L, et al. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. International Health 2012;4:153-63.
50. Amato VS, Nicodemo AC, Amato JG, Boulos M, Neto VA. Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome). J Antimicrob Chemother 2000; 46:341-2.
51. Ben Salah A, Ben Messaoud N, Guedri E, et al. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 2013; 368:524-32.